Examples of OMS103 in a sentence
Item 1.02 Termination of a Material Definitive AgreementIn anticipation of its discontinuance of its development of OMS103 and subsequent entry of the Agreement with Fagron, on June 9, 2015, Omeros delivered to Hospira Worldwide Inc., or Hospira, a notice terminating the parties’ Commercial Supply Agreement, effective October 9, 2007, or the Supply Agreement, for the commercial supply of OMS103HP-S.
OMS103 has been developed for use during arthroscopic procedures, including partial meniscectomy surgery.
Omeros will incur no further development costs, other than maintaining the licensed intellectual property, in connection with OMS103.
You agree to promptly notify GTJAF of any (actual or envisaged) breach by any of the Authorized Users of any of the obligations described here above.
For a period of twelve (12) months after the Effective Date in the case of the OMS103 Product and upon the launch of any other Licensed Product added to this Agreement, or such longer time as Omeros may agree in its sole discretion, Omeros shall cooperate with JCB by using reasonable efforts to make appropriate personnel available, at no charge for time but with out-of-pocket costs reimbursable by JCB, to respond to questions that JCB may raise with respect to the Licensed Know-How.
Under the terms of the Agreement, upon commercialization, Omeros will receive payments representing a substantial majority share of gross revenue from future OMS103 product sales within the United States, which revenue share will not be less than a minimum per unit amount.
OMS103 is covered by three issued U.S. patents and four pending U.S. patent applications, together with 32 issued patents and 13 pending patent applications in foreign markets.
Baptised Catholic children resident in the parish of Our Lady of the Annunciation & St Bernadette (the part of the parish formerly referred to as St Marie's, Standish).
Pursuant to the Agreement, Omeros granted Fagron an exclusive, royalty-free license to the OMS103 intellectual property, manufacturing information and clinical data to produce on a large scale registered basis and commercialize OMS103 in the United States.
We note that, in addition to the above, Omeros holds IP on its OMS103 candidate via issued patents slated to expire as late as September 24, 2022 and pending claims that may, if granted, expire as late as August 3, 2032.